688202 Shanghai Medicilon Inc.
- 29.77
- +0.17+0.57%
Shanghai Medicilon Inc. News
Shanghai medicilon inc. (688202.SH): has repurchased 26,400 shares of company stock.
On June 4th, Gelonhui reported that Shanghai Medicilon Inc. (688202.SH) has cumulatively repurchased 26,353 shares of the company's stock through the Shanghai Stock Exchange auction trading system as of May 31, 2024, accounting for 0.0196% of the total outstanding shares. The highest and lowest repurchase prices were 32.55 yuan/share and 32.44 yuan/share, respectively. The total amount paid was RMB 857,100.20 (excluding stamp duty, transaction fees, and other expenses).
Medici (688202.SH): Initial repurchase of 26,353 shares
Gelonghui (688202.SH) announced on May 30, 2024, that on May 30, 2024, the company repurchased 26,353 shares for the first time through centralized bidding. The repurchased shares accounted for 0.0196% of the company's total share capital, the highest transaction price was 32.55 yuan/share, the minimum transaction price was 32.44 yuan/share, and the total transaction amount was 857,100.20 yuan (excluding transaction fees such as stamp duty and transaction commissions).
Individual Investors Are Shanghai Medicilon Inc.'s (SHSE:688202) Biggest Owners and Were Hit After Market Cap Dropped CN¥385m
Key Insights Significant control over Shanghai Medicilon by individual investors implies that the general public has more power to influence management and governance-related decisions 50% of the bu
Medici (688202.SH): The repurchase period has expired and 745,200 shares have actually been repurchased
Gelonghui, May 13, 丨 Medici (688202.SH) announced that as of May 12, 2024, the company's share repurchase period has expired. The implementation of the share repurchase plan has been completed. 745,166 shares of the company's shares have been actually repurchased through the Shanghai Stock Exchange trading system, accounting for 0.5533% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share. The lowest price was 34.90 yuan/share, the average repurchase price was 53.66 yuan/share, and the total amount of capital paid was RMB 53.66 per share 39,982,446.20 yuan (excluding stamp duty)
Medici (688202.SH): Accumulated cost of 378.75 million yuan to buy back 0.5136% of the shares
On May 7, GLONGHUI (688202.SH) announced that in April 2024, the company had repurchased a total of 84,412 shares of the company through centralized bidding transactions, accounting for 0.0627% of the company's total share capital. The highest price of the repurchase transaction was 35.48 yuan/share, the lowest price was 34.90 yuan/share, and the total capital paid was 2,976,090.07 yuan (excluding transaction fees such as stamp duty and transaction commissions). As of April 30, 2024, the company has repurchased a total of 691 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system.
Medici (688202.SH) reported first-quarter results with a net loss of 375.5557 million yuan
Medici (688202.SH) released its report for the first quarter of 2024, achieving revenue of 260 million yuan, with...
Medici (688202.SH): The actual controller proposed that the company buy back the shares again
Gelonghui, April 23 | Medici (688202.SH) announced that it received a “Letter on Proposal to Repurchase the Company's Shares” from Mr. Chen Jinzhang, the actual controller and chairman of the company, and Mr. CHUN-LINCHEN, the actual controller, director and general manager. Mr. Chen Jinzhang and Mr. CHUN-LINCHEN proposed that the company use their own funds to buy back some of the RMB common shares already issued by the company through centralized bidding transactions through the Shanghai Stock Exchange trading system. The total amount of repurchase capital is not less than RMB 10 million, not more than RMB 2
Medici (688202.SH): Net loss of 33.21 million yuan in 2023 turned into a year-on-year loss
On April 23, GLONGHUI (688202.SH) released its 2023 annual report. Operating income was 1,366 billion yuan, down 17.68% year on year, net loss of 33.21 million yuan, which turned into loss year on year, after deducting non-net loss of 57.616 million yuan. The basic income per share was -0.26 yuan.
Medici (688202.SH): Accumulated cost of 34.899 million yuan to buy back 0.45% of shares
Gelonghui, April 1 | Medici (688202.SH) announced that as of March 31, 2024, the company had repurchased 607,326 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 0.4510% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share, the lowest price was 38.03 yuan/share, and the total amount of capital paid was RMB 34,899,240.78 (excluding transaction fees such as stamp duty and transaction fees).
Medici (688202.SH): Has reached strategic cooperation with many AI pharmaceutical companies
Gelonghui, March 15 | Medici (688202.SH) said on the investor interactive platform that the company will respond positively to changes in the industry and market environment, continue to cultivate its main business, continue to optimize operations, increase domestic and foreign market expansion efforts, improve the efficiency of project implementation and project delivery, and ensure orderly operation. The company will continue to consolidate pre-clinical integrated comprehensive R&D service capabilities, and while expanding its business scale, actively promote various measures to improve quality and efficiency to improve operational efficiency and profitability. The company has always paid close attention to the development trend of AI technology and has reached strategic cooperation with many AI pharmaceutical companies
Is Shanghai Medicilon (SHSE:688202) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Medici (688202.SH): 557,500 shares have been repurchased
Gelonghui (688202.SH) announced on March 4, 2024, that as of February 29, 2024, the company had repurchased 557,526 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 0.4140% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share, the lowest price was 38.03 yuan/share, and the total amount of capital paid was RMB 32,910,359.69 (excluding transaction fees such as stamp duty and transaction fees).
Medici (688202.SH) performance report: 2023 net loss of 308.773 million yuan
On February 23, GLONGHUI (688202.SH) announced its 2023 annual results report. During the reporting period, the company achieved operating income of 140,26.431 million yuan, a year-on-year decrease of 15.45%; realized net profit attributable to owners of the parent company - 30.773 million yuan, a year-on-year decrease of 109.13%; realized net profit attributable to the owners of the parent company after deducting non-recurring gains and losses - 55.1365 million yuan, a year-on-year decrease of 117.95%.
Medici (688202.SH): At this stage, specialized overseas BD teams have been deployed and team building has been continuously strengthened in the US, Europe, Japan, and South Korea
Gelonghui, Feb. 7 | Medici (688202.SH) recently said during a survey receiving institutional investors that at this stage, the company has deployed specialized overseas BD teams and continuously strengthened team building in the US, Europe, Japan and South Korea. In 2023, the company has arranged more than 30 exhibitions and conferences in the US, Europe, Japan, South Korea, etc., while increasing the frequency of regular expansion of research teams, gradually establishing a marketing and sales system adapted to overseas market competition, and continuing to strengthen customer follow-up development, especially for medium and large foreign pharmaceutical companies and high-quality biotechnology companies. Currently, the company is in Boston, USA
Medici (688202.SH): The price of experimental monkeys has dropped recently
Gelonghui, Feb. 7: Medici (688202.SH) recently said during a survey from institutional investors that the price of experimental monkeys has dropped recently. The company has actively adopted various measures such as diversifying procurement channels and deepening cooperation with experimental animal suppliers to ensure the stable supply of the company's experimental animals, especially experimental monkeys, which can meet the company's operating needs.
Medici (688202.SH): The ban on 126.904 million restricted shares was lifted on February 19
On February 1, GLONGHUI (688202.SH) announced that the total number of shares in circulation in the company's current stock listing was 12.694 million shares. The stock listing and circulation date is February 19, 2024.
Medici (688202.SH): As of January 31, 488,400 shares have been repurchased
Gelonghui, January 31 | Medici (688202.SH) announced that as of January 31, 2024, the company had repurchased 488,426 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 0.3627% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share, the lowest price was 42.32 yuan/share, and the total amount of capital paid was RMB 29,952,362.56 (excluding transaction fees such as stamp duty and transaction fees).
Shanghai Medicilon Inc.'s (SHSE:688202) Stock Price Dropped 15% Last Week; Retail Investors Would Not Be Happy
Key Insights Significant control over Shanghai Medicilon by retail investors implies that the general public has more power to influence management and governance-related decisions 51% of the busine
Medici (688202.SH): Actual Controllers Increase Co-Actors and Proposed Internal Transfer of Shares between Coordinating Actors
Gelonghui, January 12 | Medici (688202.SH) announced that due to personal asset planning requirements, Mr. Chen Jinzhang, one of the actual controllers of Shanghai Medici Biomedical Co., Ltd., plans to hold 100% of the shares to Mr. Chen Guokai (the two are father and son) and managed by Zefeng Ruixi Private Equity Fund Management (Guangdong) Co., Ltd. as the private equity fund manager (“Zefeng Guangxin No. 1 Fund” for short) to transfer no more than 2,693,461 shares of the company's shares, accounting for no more than 2,693,461 shares of the company's shares Over 2.00%. Chen Jinzhang
Medici (688202.SH): Accumulated cost of 19988,700 yuan to buy back 0.22% of the shares
Gelonghui, January 2, 丨 Medici (688202.SH) announced that as of December 31, 2023, the company had repurchased 296,414 shares of the company's shares through centralized bidding transactions. The repurchased shares accounted for 0.2201% of the company's total share capital. The highest price of the repurchase transaction was 74.95 yuan/share, the lowest price was 63.05 yuan/share, and the total amount of capital paid was RMB 19,988,695.81 yuan.
Analysis
Price Target
No Data
